Hepatocellular Carcinoma: a Comprehensive Review Of Biomarkers, Clinical Aspects, and Therapy

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2017 May 27

PMID 28545181

Citations 65

Authors

Nathalia Martines Tunissiolli

Marcia Maria Urbanin Castanhole-Nunes

Patricia Matos Biselli-Chicote

Erika Cristina Pavarino

Renato Ferreira da Silva

Rita de Cassia Martins Alves da Silva

Eny Maria Goloni-Bertollo

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a cause of several deaths related to cancer worldwidely. In early stage, curative treatments such as surgical resection, liver transplant and local ablation can improve the patient ´s survival. However, the disease is detected in advanced stage; moreover some available therapies are restricted to palliative care and local treatment. Early detections of HCC and adequate therapy are crucial to increase survival as well as to improve the patient´s quality of life. Therefore, researchers have been investigating molecular biomarkers with high sensibility and reliability as Golgi 73 protein (GP73), Glypican-3 (GPC3), Osteopontin (OPN), microRNAs and others. MicroRNAs can regulate important pathways on carcinogenesis, as tumor angiogenesis and progression. So, they can be considered as possible markers of prognosis in HCC, and therapeutic target for this tumor type. In this review, we discuss the recent advances related to the cause (highlighting the main risk factors), treatment, biomarkers, clinic aspects, and outcome in hepatocellular carcinoma.

Citing Articles

Dose-Dependent PFESA-BP2 Exposure Increases Risk of Liver Toxicity and Hepatocellular Carcinoma.

Kostecki G, Chuang K, Buxton A, Dakshanamurthy S Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996819 PMC: 11854358. DOI: 10.3390/cimb47020098.

Targeted delivery of curcumin and CM11 peptide against hepatocellular carcinoma cells based on binding affinity of PreS1-coated chitosan nanoparticles to SB3 protein.

Rahmani D, Taheri R, Moosazadeh Moghaddam M Amino Acids. 2025; 57(1):12.

PMID: 39862295 PMC: 11762422. DOI: 10.1007/s00726-024-03438-x.

Autophagy-based therapy for hepatocellular carcinoma: from standard treatments to combination therapy, oncolytic virotherapy, and targeted nanomedicines.

Rahdan F, Abedi F, Dianat-Moghadam H, Zamani Sani M, Taghizadeh M, Alizadeh E Clin Exp Med. 2024; 25(1):13.

PMID: 39621122 PMC: 11611955. DOI: 10.1007/s10238-024-01527-5.

Recent Trends in Liver Cancer: Epidemiology, Risk Factors, and Diagnostic Techniques.

Kale S, Karande G, Gudur A, Garud A, Patil M, Patil S Cureus. 2024; 16(10):e72239.

PMID: 39583507 PMC: 11584332. DOI: 10.7759/cureus.72239.

Integrating molecular, biochemical, and immunohistochemical features as predictors of hepatocellular carcinoma drug response using machine-learning algorithms.

Matboli M, Al-Amodi H, Khaled A, Khaled R, Ali M, Kamel H Front Mol Biosci. 2024; 11:1430794.

PMID: 39479501 PMC: 11521808. DOI: 10.3389/fmolb.2024.1430794.

References

Rahimi R, Trotter J . Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence. Ann Gastroenterol. 2015; 28(3):323-330. PMC: 4480168. View

Law P, Ching A, Chan A, Wong Q, Wong C, To K . MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis. 2012; 33(6):1134-41. DOI: 10.1093/carcin/bgs130. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Sun V, Sarna L . Symptom management in hepatocellular carcinoma. Clin J Oncol Nurs. 2008; 12(5):759-66. PMC: 2881685. DOI: 10.1188/08.CJON.759-766. View

Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce C . MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med. 2009; 12(6A):2189-204. PMC: 4514099. DOI: 10.1111/j.1582-4934.2008.00533.x. View

Yang J, Roberts L . Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010; 7(8):448-58. PMC: 3926946. DOI: 10.1038/nrgastro.2010.100. View

McGlynn K, London W . The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011; 15(2):223-43, vii-x. PMC: 4141529. DOI: 10.1016/j.cld.2011.03.006. View

Lencioni R . Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer. 2013; 1(1):41-50. PMC: 3747539. DOI: 10.1159/000339019. View

Lok A, Sterling R, Everhart J, Wright E, Hoefs J, Di Bisceglie A . Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2009; 138(2):493-502. PMC: 2819612. DOI: 10.1053/j.gastro.2009.10.031. View

10.

Minguez B, Lachenmayer A . Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis Markers. 2011; 31(3):181-90. PMC: 3826804. DOI: 10.3233/DMA-2011-0841. View

11.

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

12.

Fan S, Eiser C, Ho M . Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroenterol Hepatol. 2010; 8(7):559-64.e1-10. DOI: 10.1016/j.cgh.2010.03.008. View

13.

Kedmi M, Ben-Chetrit N, Korner C, Mancini M, Bossel Ben-Moshe N, Lauriola M . EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. Sci Signal. 2015; 8(368):ra29. DOI: 10.1126/scisignal.2005866. View

14.

Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann J, Thiele F . T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice. Gastroenterology. 2015; 149(4):1042-52. DOI: 10.1053/j.gastro.2015.05.055. View

15.

Liu Z, Wang J, Mao Y, Zou B, Fan X . MicroRNA-101 suppresses migration and invasion via targeting vascular endothelial growth factor-C in hepatocellular carcinoma cells. Oncol Lett. 2016; 11(1):433-438. PMC: 4727073. DOI: 10.3892/ol.2015.3832. View

16.

Waisberg J, Saba G . Wnt-/-β-catenin pathway signaling in human hepatocellular carcinoma. World J Hepatol. 2015; 7(26):2631-5. PMC: 4651907. DOI: 10.4254/wjh.v7.i26.2631. View

17.

Okada H, Honda M, Campbell J, Takegoshi K, Sakai Y, Yamashita T . Inhibition of microRNA-214 ameliorates hepatic fibrosis and tumor incidence in platelet-derived growth factor C transgenic mice. Cancer Sci. 2015; 106(9):1143-52. PMC: 4582983. DOI: 10.1111/cas.12730. View

18.

Kumar M, Panda D . Role of supportive care for terminal stage hepatocellular carcinoma. J Clin Exp Hepatol. 2015; 4(Suppl 3):S130-9. PMC: 4284220. DOI: 10.1016/j.jceh.2014.03.049. View

19.

Li C, Deng M, Hu J, Li X, Chen L, Ju Y . Chronic inflammation contributes to the development of hepatocellular carcinoma by decreasing miR-122 levels. Oncotarget. 2016; 7(13):17021-34. PMC: 4941368. DOI: 10.18632/oncotarget.7740. View

20.

Baines A, Xu D, Der C . Inhibition of Ras for cancer treatment: the search continues. Future Med Chem. 2011; 3(14):1787-808. PMC: 3347641. DOI: 10.4155/fmc.11.121. View